Shorter Overall Survival (OS) in HER2-positlve (HER2+) metastatic breast cancer (MBC) patients (pts) treated with trastuzumab (T) ± chemotherapy (CT) and overexpressing HER3 by immunohistochemistry (IHC)

被引：0
|
作者：
Gori, S.
Sidoni, A. [2 ]
Colozza, M.
Mameli, M. G. [2 ]
Fenocchio, D. [1 ]
Minenza, E.
Foglietta, J.
Stocchi, L.
De Angelis, V. [3 ]
Crino, L.
机构：
[1] Santa Maria Misericordia Hosp, Pathol Anat & Histol Serv, Perugia, Italy
[2] Univ Perugia, Inst Pathol Anat & Histol, I-06100 Perugia, Italy
[3] ASL2 Perugia, Palliat Cure Serv, Perugia, Italy
来源：
EJC SUPPLEMENTS | 2009年 / 7卷 / 02期
关键词：
D O I：
10.1016/S1359-6349(09)70981-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：287 / 287
页数：1
相关论文
共 50 条
  • [21] Role of HER3 expression and PTEN loss in patients with HER2-overexpressing metastatic breast cancer (MBC) who received taxane plus trastuzumab treatment
    Park, Y. H.
    Jung, H. A.
    Choi, M. K.
    Chang, W.
    Choi, Y. L.
    Do, I-g
    Ahn, J. S.
    Im, Y-H
    BRITISH JOURNAL OF CANCER, 2014, 110 (02) : 384 - 391
  • [22] Role of HER3 expression and PTEN loss in patients with HER2-overexpressing metastatic breast cancer (MBC) who received taxane plus trastuzumab treatment
    Y H Park
    H A Jung
    M K Choi
    W Chang
    Y L Choi
    I-g Do
    J S Ahn
    Y-H Im
    British Journal of Cancer, 2014, 110 : 384 - 391
  • [23] Role of HER3 expression and PTEN loss in patients with HER2-overexpressing metastatic breast cancer (MBC) patients who received taxane plus trastuzumab treatment
    Park, Yeon Hee
    Jung, Hyun As
    Chang, Won Jin
    Choi, Moon Ki
    Hong, Jung Yong
    Ok, Oh-Nam
    Seo, Jeong Ju
    Choi, Yoon-La
    Do, Ingu
    Ahn, Jun Seok
    Im, Young-Hyuck
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [24] Retreatment with trastuzumab (T)-based therapy in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (MBC) resistant to lapatinib (L)-based therapy.
    Gori, S.
    Montemurro, F.
    Spazzapan, S.
    Metro, G.
    Foglietta, J.
    Bisagni, G.
    Ferzi, A.
    Silva, R. R.
    Gamucci, T.
    Clavarezza, M.
    Stocchi, L.
    Fabi, A.
    Cognetti, F.
    Torrisi, E.
    Crivellari, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [25] Brain metastases (BM) in patients treated with trastuzumab for HER2 overexpressing metastatic breast cancer (MBC): Incidence and survival.
    Stemmler, L
    Kahlert, S
    Siekiera, W
    Untch, M
    Heinrich, B
    Heinemann, V
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 131S - 131S
  • [26] Population pharmacokinetics of trastuzumab in patients With HER2+ metastatic breast cancer
    Bruno, R
    Washington, CB
    Lu, JF
    Lieberman, G
    Banken, L
    Klein, P
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2005, 56 (04) : 361 - 369
  • [27] Population pharmacokinetics of trastuzumab in patients With HER2+ metastatic breast cancer
    Rene Bruno
    Carla B. Washington
    Jian-Feng Lu
    Grazyna Lieberman
    Ludger Banken
    Pamela Klein
    Cancer Chemotherapy and Pharmacology, 2005, 56 : 361 - 369
  • [28] HER2, EGFR, PIK3CA mutations in HER2+metastatic breast cancer (MBC) patients (pts) treated with trastuzumab (T): Incidence and correlation with response
    Gori, S.
    Ludovini, V.
    Colozza, M.
    Pistola, L.
    Tofanetti, F. R.
    Flacco, A.
    Foglietta, J.
    Minenza, E.
    Stocchi, L.
    De Angelis, V.
    Crino, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [29] Phase I study of LJM716, BYL719, and trastuzumab in patients (pts) with HER2-amplified (HER2+) metastatic breast cancer (MBC).
    Shah, Payal Deepak
    Chandarlapaty, Sarat
    Dickler, Maura N.
    Ulaner, Gary
    Zamora, Stephen James
    Sterlin, Valentina
    Iasonos, Alexia
    Coughlin, Christina Marie
    Morozov, Alex
    Ero, Joy
    Rosen, Neal
    Gilewski, Teresa
    Fornier, Monica Nancy
    Sklarin, Nancy T.
    Berger, Michael F.
    Moynahan, Mary Ellen
    Hudis, Clifford A.
    Baselga, Jose
    Modi, Shanu
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [30] A multicenter study of trastuzumab N and vinorelbine (N) as first and second line therapy for patients (pts) with HER2-positive metastatic breast cancer (HER2+ MBC).
    Franquesa, RM
    Centelles, M
    Villadiego, K
    Janáriz, J
    Arcusa, A
    Cirera, L
    Segui, M
    Saigi, E
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 94S - 94S
12345